Alpha Wave Ventures
Assembly Line
HistoSonics Announces Oversubscribed $102 Million Series D Financing to Scale Launch of Non-Invasive Histotripsy Platform
HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced the completion of an oversubscribed $102 million Series D financing. The round was led by Alpha Wave Ventures, a world leader in growth stage investments, with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation - JJDC, Inc. (JJDC), Venture Investors, Lumira Ventures, Yonjin Venture, the State of Wisconsin Investment Board, and others.
Histotripsy is a novel form of focused ultrasound that uses high amplitude, very short pulses to create a “bubble cloud” that is designed to mechanically destroy and liquefy targeted liver tumors. These bubble clouds form and collapse in microseconds, creating mechanical forces strong enough to destroy tissue at cellular and sub-cellular levels in a non-invasive and non-thermal method. Histotripsy offers a promising alternative to treatments such as surgery, radiation and chemotherapy, which often have significant side effects.
The Series D funding will be used to accelerate category defining advancements to its non-invasive histotripsy platforms, support commercial growth in the US and in planned global markets, and initiate the company’s innovative, prospective BOOMBOX Master Study that will evaluate HistoSonics’ Edison System for the treatment of liver tumors across multidisciplinary users. The Edison Histotripsy System was granted FDA De Novo clearance in October 2023. HistoSonics is currently partnering with leading institutions across the US and internationally in developing multi-disciplinary histotripsy liver programs.
Mitra Chem Secures Investment from Alpha Wave Ventures
Mitra Future Technologies, Inc. (“Mitra Chem”), a pioneering innovator in North American lithium-ion battery materials, announced an investment from Alpha Wave Ventures as part of the company’s Series B funding round. As part of the investment, Elan Frantz has joined the company’s Board of Directors. Alpha Wave joins other distinguished investors in this round, such as General Motors, Zeon, InQTel, Techmet-Mercuria, and GS Futures.
Alpha Wave joins Mitra Chem amidst several breakthroughs, with Mitra Chem recently announcing its successful synthesis of multi-ton Lithium Iron Phosphate (LFP) cathode powder samples that meet industry-leading electric vehicle (EV) specifications. Mitra Chem aims to achieve mass production of their iron-rich cathodes by 2026, paving the way for widespread adoption of next-generation, IRA-compliant battery technologies.